Partners

MDS Nordion offers tailored solutions, leading expertise, and service capabilities for radiopharmaceutical development, clinical and commercial manufacturing, and radiation-based medical device development.

Imaging

Partner	Partner's Product	MDS Nordion's Medical Isotope	MDS Nordion's Services and Expertise
	123I β-amyloid compound Avid is developing novel radiopharmaceuticals to diagnose and monitor Alzheimer's disease and other pathologies.	Iodine-123	Radiolabelling feasibility
	Altropane® The Altropane molecular imaging agent is being developed to aid in the diagnosis of Parkinson's Disease.	Iodine-123	Process development Scale-up Clinical supply
	Zemiva™ (Iodofiltic Acid I123) Zemiva is being developed to detect and manage cardiac ischemia by imaging metabolic changes in the heart.	Iodine-123	Process development Scale-up Clinical supply

Therapy

Partner	Partner's Product	MDS Nordion's Medical Isotope	MDS Nordion's Services and Expertise
	Neuradiab (I-131 anti- tenascin 81C6 mAb) Bradmer Pharmaceuticals' novel molecular targeting agent under development for the treatment of Glioblastoma Multiforme (GBM).	Iodine-131	Process development Scale-up Clinical trial manufacture
	Bexxar® (Iodine I131Tositumomab) The Bexxar Therapeutic Regimen is indicated for the treatment of patients with CD 20 antigen expressing relapsed or refractory, low grade, follicular, or transformed non-Hodgkin's lymphoma (NHL), including patients with Rituximab-refractory non-Hodgkin's lymphoma.	Iodine-131	Process development Scale-up Manufacture
	Zevalin® (Ibritumomab Tiuxetan) Zevalin, as part of the Zevalin therapeutic regimen, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell NHL, including patients with Rituximab-refractory follicular NHL.	Yttrium-90	Development of Yttrium-90 Chloride Sterile Solution for clinical and commercial distribution
	Iotrex® Radiotherapy Solution (I125 HBS) Iotrex is a radiotherapy solution to be used in the GliaSite® Radiation Treatment Delivery System, indicated for the treatment of newly diagnosed, metastatic and recurrent brain tumors be delivering radiation from within the cavity created by the surgical removal of the tumor.	Iodine-125	Process development Manufacture
	Azedra™ (Ultratrace™ Iobenguane I131) Under development for the treatment of neuroblastoma and pheochromacytoma.	Iodine-131	Process development

  Back to Top